Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Sanofi-Aventis Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (111)
Prescription medicine registration (6)
ARTG (4)
Designation or determination (3)
Australian public assessment report (AusPar) (2)

Date

(-) 2019 (126)
2026 (5)
2025 (26)
2024 (41)
2023 (48)
2022 (26)
2021 (101)
2020 (61)
2018 (40)
2017 (21)
2016 (22)
2015 (14)
2014 (22)
2013 (8)
2012 (3)
2010 (2)
2009 (11)
2008 (5)
2007 (12)
2006 (10)
2005 (12)
2004 (5)
2003 (2)
2002 (6)
2001 (3)
2000 (11)
1999 (5)
1998 (4)
1997 (1)
1996 (7)
1995 (2)
1994 (6)
1993 (6)
1991 (19)

Search

Filters applied:

2019

Clear all

Sponsor content

126 result(s) found, displaying 31 to 40

VALLERGAN FORTE alimemazine (trimeprazine) tartrate 6mg/mL oral liquid bottle Cancelled under Section 30(1)(c) of the Act

25 September 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
VALLERGAN alimemazine (trimeprazine) tartrate 10mg tablet bottle Cancelled under Section 30(1)(c) of the Act

21 August 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
VALLERGAN FORTE alimemazine (trimeprazine) tartrate 6mg/mL oral liquid solution bottle (NZ) Cancelled under Section 30(1)(c) of the Act

21 August 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FLUQUADRI (Sanofi-Aventis Australia Pty Ltd)

15 August 2019

Prescription medicine registration

Active ingredients: influenza virus haemagglutinin.
Notice for cemiplimab (Sanofi-Aventis Australia Pty Ltd)

16 July 2019

Designation or determination

Provisional approval
RENAGEL sevelamer hydrochloride 400 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
AusPAR: Sarilumab (rch)

24 June 2019

Australian public assessment report (AusPar)

Australian Public Assessment for Sarilumab (rch)
Notice for isatuximab (Sanofi-Aventis Australia Pty Ltd)

6 June 2019

Designation or determination

Orphan drug
ROXITHROMYCIN GH roxithromycin 150 mg tablet blister pack Cancelled under Section 30(1) (c) of the Act

28 May 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
ROXITHROMYCIN GH roxithromycin 300 mg tablet blister pack Cancelled under Section 30(1) (c) of the Act

28 May 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.